Survey of proper use and occurrence of hyperkalemia after administration of MINNEBRO tablets in patients with hypertension -MID-NET Cohort Study-

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031200204

Enrollment

3100

Registered

2020-11-27

Start date

2009-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Prescription of MINNEBRO tablets has commenced during the enrollment period (May 13, 2019 to May 31, 2023). -The diagnosis of hypertension exists between the first prescription day and 30 days before the first prescription day of this drug during the enrollment period. -The date of the earliest medical record after the start date of the data period is 180 days or more prior to the date of the first prescription of this drug.

Exclusion criteria

Exclusion criteria: NONE

Design outcomes

Primary

Measure	Time frame
Conduct serum potassium testing,, Development of hyperkalemia	—

Contacts

Public ContactContact for GPSP

Daiichi Sankyo Co.,Ltd.

contact_gpsp@daiichisankyo.co.jp+81-3-6225-1059

Outcome results